Key Takeaways:
Daiichi Sankyo Co. unveiled a five-year business plan that targets more than 2.3 trillion yen ($14.7 billion) in oncology revenue by 2030, a strategy centered on its industry-leading antibody-drug conjugate (ADC) portfolio.
"Our new five-year business plan represents a defining and transformative phase for Daiichi Sankyo," Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo, said in a May 11 statement. "By leveraging our strengths in science and technology... Daiichi Sankyo is committed to delivering innovative medicines to patients faster while driving sustainable growth."
The Tokyo-based drugmaker is aiming for total revenue of three trillion yen and an operating profit of more than 600 billion yen by the end of fiscal year 2030. The plan includes five practice-changing launches planned for fiscal year 2026 alone across its DXd ADC portfolio, including new breast cancer indications for Enhertu and Datroway.
The aggressive targets put Daiichi Sankyo on a path to become a top five global oncology company by 2035, seeking to reach more than 700,000 new patients annually by that year. The plan relies on maximizing the value of its DXd ADC platform, which has already produced major revenue drivers and changed treatment standards in some cancers.
The foundation of the growth plan is the company's ADC technology, which uses antibodies to deliver potent cancer-killing toxins directly to tumor cells. The company's first major success, Enhertu, developed in partnership with AstraZeneca, has become the most successful ADC ever by revenue.
"Enhertu has changed the classification and treatment of breast cancer," said Ken Keller, Global Head of Oncology Business at Daiichi Sankyo. "Datroway, our second DXd antibody drug conjugate, is on its way to changing the treatment paradigm for triple negative breast cancer." The company plans to expand its leadership into lung cancer, with more than 10 new indication launches planned for that tumor type.
While the ADC platform is the current growth engine, Daiichi Sankyo is also strengthening its research and development through a "breakthrough generating technology" approach. The company aims to identify new drug discovery platforms by 2030, including multi-specific antibodies and targeted protein degradation, to sustain growth beyond the next decade.
The company's ambitious plan comes shortly after it reported a significant hit to its fiscal 2025 profit forecast due to costs associated with its precautionary ADC manufacturing strategy. The firm is navigating a complex global supply chain and intense competition from other major oncology players like Johnson & Johnson, Merck, and its own partner, AstraZeneca.
The new strategy signals Daiichi Sankyo's confidence in its ADC platform to challenge established oncology leaders and significantly expand its market share. Investors will be closely watching the execution of its 20 planned indication launches and progress in developing its next-generation technology pipeline.
This article is for informational purposes only and does not constitute investment advice.
